AUTHORS
Prajish Iyer, PhD, Alexey V. Danilov, MD, PhD2, Nicole Lamanna, MD3, Lili Wang, MD, PhD4
AFFILIATIONS
1 Columbia University, New York, New York, United States
2 City of Hope National Medical Center, Duarte, California, United States
3 Columbia University, New York, New York, United States
4 Columbia University, New York, New York, United States
ABSTRACT
Despite advances in chronic lymphocytic leukemia (CLL) therapy, Richter's transformation (RT), the progression of CLL to aggressive lymphoma, remains incurable. MYC signaling is dysregulated in ~70% of RT cases, with ~30–40% harboring loss-of-function mutations in the MYC suppressor MGA. We previously demonstrated that MGA loss promotes CLL-to-RT transformation by rewiring glucose carbon flux toward glycerol-3-phosphate (Gro3P), increased glycerolipid metabolism, lipid droplet (LD) accumulation, triglyceride synthesis, and oxidative phosphorylation (OXPHOS), thereby revealing a tight metabolic coupling between LDs and mitochondrial function in RT.
Peridroplet mitochondria (PDM) are a specialized subpopulation of mitochondria that are physically attached to LD via stable tethering proteins. PDM has been demonstrated to promote cancer cell survival by integrating lipid metabolism with mitochondrial ATP production in lung cancers and liver diseases, emerging as a potential therapeutic target. However, their presence and roles in RT progression remain unknown.
To delineate the role of PDM in RT, we used three independent human RT patient-derived xenograft (RT-PDX) splenic B cells, healthy donor B cells (normal B) (n =2), CLL B cells (n = 3), CLL cell lines (n =2; HG3, MEC1), DLBCL cell lines (n = 3 : SUDHL4, LY3 and U2932), Burkitt lymphoma (BL) cell lines/xenografts ( n =2; positive controls for LD : RAJI and RAMOS) using transmission electron microscopy (TEM), confocal imaging, and functional metabolic assays such as BODIPY-493 based neutral LD flow cytometry, citrate synthase TCA cycle activity assays and C12 based fatty acid incorporation flow cytometry assays.
TEM revealed increased LD accumulation in RT-PDX cells and the DLBCL cell lines (SUDHL4, LY3 and U2932), BL cell lines, and xenografts (RAJI and RAMOS) compared with human CLL and normal B cells. PDM were readily observed in RT-PDX and SUDHL4 and LY3 cells but were rare in human CLL B, CLL cell lines and normal B cells. Quantification of LD showed significantly higher LD volume in RT models compared with CLL-DLBCL-BL cell lines, with the greatest LD accumulation in RT-PDX-derived tumors. In addition, RT-PDX cells and SUDHL4 cell lines all exhibited a significantly higher percentage of mitochondria-LD interactions than CLL patient, normal B cells (*P< 0.05). PDM were independently validated in Mito-DsRed2-expressing SUDHL4 cells by confocal microscopy using BODIPY 493/503 staining to visualize lipid droplet-mitochondria interactions. Consistent with increased LD accumulation, our immunoblotting results reveal that RT-PDX cells have significantly increased expression of proteins involved in LD biogenesis and fatty acid metabolism, including SREBF1, CPT1A (fatty acid synthesis and oxidation), DGAT2, PLIN5 (PDM-associated proteins), PLIN2, and FATP4 (LD surface and FA transport), compared with untreated patient CLL B cells (n = 5). These findings identify enhanced lipid storage and PDM formation as previously unrecognized features of RT.
To evaluate the therapeutic potential of targeting PDM, we tested SEN101, a novel PDM inhibitor, alone and in combination with venetoclax, a clinically relevant BCL2 inhibitor for CLL and RT, using CLL and DLBCL cell line models. Combination treatment with SEN101 and venetoclax enhanced antitumor activity, reducing the IC50 from 1.33 to 0.0079 µM in SUDHL4 cells and from 0.61 to 0.0071 µM in SUDHL4 MGA-KO cells, compared with SEN101 monotherapy, as measured by a CCK8-based colorimetric cell viability assay. Further, the combination of venetoclax+SEN101 impaired mitochondrial function, reduced fatty acid uptake, and increased cellular ROS detected by flow cytometry assays, supporting co-targeting of PDM and BCL2 as a therapeutic strategy in RT/DLBCL. Mechanistically, PDM inhibition reduced citrate synthase activity and oxygen consumption, as measured by colorimetric and Seahorse mitochondrial stress assays, respectively. Further in vivo validation is ongoing to evaluate the therapeutic efficacy and survival benefit of SEN101 in RT-PDX models, alongside EM studies in primary RT patient samples to assess PDM morphology and treatment-induced structural alterations.
Collectively, these findings identify PDM as a previously unrecognized metabolic dependency that sustains lipid storage and mitochondrial bioenergetics in RT and establish disruption of the PDM-lipid droplet axis as a therapeutic strategy for this otherwise incurable disease.
DISCLOSURES
Prajish Iyer, PhD: No relevant conflicts of interest to declare.